Securities Analyst Recommendations: Atlassian Corporation Plc (TEAM), The Clorox Company (CLX)

Atlassian Corporation Plc (NASDAQ:TEAM) tinted gains of +0.16% (+0.15 points) to US$95.65. The volume of 0.93 Million shares climbed down over an trading activity of 1.67 Million shares. EPS ratio determined by looking at last 12 month figures is -1.28. Over the same time span, the stock marked US$98.21 as its best level and the lowest price reached was US$47.74. The corporation has a market cap of US$23.24 Billion.

Atlassian Corporation Plc (NASDAQ:TEAM)’s earnings per share has been growing at a -51.5 percent rate over the past 5 year when average revenue increase was noted as 42.5 percent. The return on equity ratio or ROE stands at -41.3 percent while most common profitability ratio return on investment (ROI) was -3.5 percent. The company’s institutional ownership is monitored at 92.7 percent. The company’s net profit margin has achieved the current level of -36.7 percent and possesses 81.2 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 6 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 8 think it is Hold. Recently, analysts have updated the overall rating to 2.12. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

The Clorox Company (NYSE:CLX) is worth US$19.6 Billion and has recently risen 0.16% to US$153.35. The latest exchange of 1.16 Million shares is above its average trading activity of 1.12 Million shares. The day began at US$153.7 but the price moved to US$152.18 at one point during the trading and finally capitulating to a session high of US$154.56. The stock tapped a 52-week high of US$167.7 while the mean 12-month price target for the shares is US$145.6.

Currently, the stock carries a price to earnings ratio of 26.45, a price to book ratio of 28.93, and a price to sales ratio of 3.17. For the past 5 years, the company’s revenue has grown 2.1%, while the company’s earnings per share has grown 5.5%. With an institutional ownership near 81.1%, it carries an earnings per share ratio of 5.8.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 10 analysts recommended Holding these shares while 2 recommended sell, according to FactSet data. 2 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.12.